In:
Blood, American Society of Hematology, Vol. 129, No. 21 ( 2017-05-25), p. 2882-2895
Abstract:
Inhibition of RNA Pol I by CX-5461 treats aggressive AML and outperforms standard chemotherapy regimens. CX-5461 induces p53-dependent apoptosis, p53-independent cell-cycle defects and differentiation, and reduces LICs.
Type of Medium:
Online Resource
ISSN:
0006-4971
,
1528-0020
DOI:
10.1182/blood-2016-05-718171
Language:
English
Publisher:
American Society of Hematology
Publication Date:
2017
detail.hit.zdb_id:
1468538-3
detail.hit.zdb_id:
80069-7
Permalink